Agne Paner, MD, director, discusses the phase II HORIZON trial in relapsed/refractory multiple myeloma.
Agne Paner, MD
Advertisement
Articles by Agne Paner, MD
Advertisement
Latest Updated Articles
Dr. Paner on HORIZON Trial in Multiple MyelomaPublished: January 30th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5